modelR06AX18
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Acrivastine | |
| ATC code: | R06AX18 | route: | oral |
| compartments: | 1 | |
| dosage: | 8 | mg |
| volume of distribution: | 65 | L |
| clearance: | 8.6 | L/h |
| other parameters in model implementation | ||
Acrivastine is a second-generation non-sedating antihistamine used for the symptomatic relief of allergic conditions such as hay fever, urticaria, and other allergic rhinitis symptoms. It is commonly available in combination with pseudoephedrine and is approved for use in several countries.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult subjects after a single oral dose of 8 mg acrivastine.
References
Simons, FE (2002). Comparative pharmacology of H1 antihistamines: clinical relevance. The American journal of medicine 113 Suppl 9A 38S–46S. DOI:10.1016/s0002-9343(02)01436-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12517581
Simons, FE, & Simons, KJ (1999). Clinical pharmacology of new histamine H1 receptor antagonists. Clinical pharmacokinetics 36(5) 329–352. DOI:10.2165/00003088-199936050-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10384858
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)